Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00317629
Recruitment Status : Terminated (An interim analysis showed that nitric oxide patches are not enough effective)
First Posted : April 25, 2006
Last Update Posted : November 24, 2010
Universidad de Antioquia
The University of Akron
Universidad de Santander
Secretaria de Salud de Santander
Secretaria de Salud de Tolima
Information provided by:
Fundación Cardiovascular de Colombia

Brief Summary:

Cutaneous leishmaniasis is a worldwide disease, endemic in 88 countries, that has shown an increasing incidence over the last two decades. So far, pentavalent antimony compounds have been considered the treatment of choice, with a percentage of cure of about 85%. However, the high efficacy of these drugs is counteracted by their many disadvantages and adverse events. Previous studies have shown nitric oxide to be a potential alternative treatment when administered topically with no serious adverse events. However, due to the unstable nitric oxide release, the topical donors needed to be applied frequently, making the adherence to the treatment difficult. The electrospinning technique has allowed the production of a multilayer transdermal patch that produces a continuous and stable nitric oxide release. The main objective of this study is to evaluate this novel nitric oxide topical donor for the treatment of cutaneous leishmaniasis.

A double-blind, randomized, double-masked, placebo-controlled clinical trial, including 620 patients from endemic areas for leishmaniasis in Colombia was designed to investigate whether this patch is as effective as meglumine antimoniate for the treatment of cutaneous leishmaniasis but with less adverse events. Subjects with ulcers characteristic of cutaneous leishmaniasis will be medically evaluated and laboratory tests and parasitological confirmation performed. After checking the inclusion/exclusion criteria, the patients will be randomly assigned to one of two groups. During 20 days Group 1 will receive simultaneously meglumine antimoniate and placebo of nitric oxide patches while Group 2 will receive placebo of meglumine antimoniate and active nitric oxide patches. During the treatment visits, the medications will be administered daily and the presence of adverse events assessed. During the follow-up, the research group will visit the patients at days 21, 45, 90 and 180. The healing process of the ulcer, the health of the participants, recidivisms and/or reinfection will also be assessed. The evolution of the ulcers will be photographically registered. In the case that the effectiveness of the patches is demonstrated, a novel and safe therapeutic alternative for one of the most important public health problems in many countries will be available to patients.

Condition or disease Intervention/treatment Phase
Cutaneous Leishmaniasis Drug: controlled nitric oxide releasing patch Drug: meglumine antimoniate Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 178 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
Study Start Date : May 2006
Actual Primary Completion Date : January 2009
Actual Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leishmaniasis

Arm Intervention/treatment
Active Comparator: 1 Drug: meglumine antimoniate
20mg/kg daily during 20 days
Other Name: glucantime

Experimental: 2 Drug: controlled nitric oxide releasing patch
daily nitric oxide patch application during 20 days

Primary Outcome Measures :
  1. Complete reepithelization [ Time Frame: three months after the beginning of the treatment ]

Secondary Outcome Measures :
  1. Absence of reactivation and affections of the mucous membranes [ Time Frame: during the first 6 months of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women between 18 and 50 years old
  • Cutaneous ulcers of more than two weeks of evolution
  • Positive parasitological diagnosis for CL
  • Patients that voluntarily agree to participate in the study and sign the informed consent.
  • Disposition to attend all the visits punctually (initial, treatment and follow-up)
  • Acceptation of not using any other treatment for CL while in the study

Exclusion Criteria:

  • Pregnant women
  • Presence of any condition or disease that compromises the patient immunologically (i.e. diabetes, cancer, etc.) or, any other, that, based on the judgment of the researcher, could alter the course of CL.
  • Diffuse CL or more than five active lesions.
  • Mucocutaneous leishmaniasis (no lesion must be located less than 2 cm from the nasal, uro-genital, and/or anal mucous membranes or from the edge of the lips).
  • Visceral leishmaniasis
  • Complete or incomplete treatment with antimony compounds in the last three months.
  • Patients with history of hepatic, renal or cardiovascular disease.
  • Mentally or neurologically disabled patients that are considered not fit to approve their participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00317629

Layout table for location information
Fundación Cardiovascular de Colombia
Floridablanca, Santander, Colombia, 10000
Sponsors and Collaborators
Fundación Cardiovascular de Colombia
Universidad de Antioquia
The University of Akron
Universidad de Santander
Secretaria de Salud de Santander
Secretaria de Salud de Tolima
Layout table for investigator information
Principal Investigator: Patricio López-Jaramillo, MD, PhD Cardiovascular Foundation of Colombia
Principal Investigator: Daniel J Smith, PhD Akron University
Study Chair: Iván D Vélez, MD, MsC, PhD Program for the Study and Control of Tropical Diseases, PECET, Universidad de Antioquia
Study Chair: Gerardo Muñoz, PhD Universidad Industrial de Santander
Study Chair: Hernando Mosquera, MD
Study Chair: Federico A Silva, MD Cardiovascular Foundation of Colombia
Study Chair: Marcos López, PhD The University of Akron
Principal Investigator: Daniel Smith, PhD The University of Akron
Study Chair: Ligia C Rueda, MD Fundación Cardiovascular de Colombia
Study Chair: Christian F Rueda-Clausen, MD Fundación Cardiovascular de Colombia
Layout table for additonal information
Responsible Party: Victor Raúl Castillo Mantilla, Fundación Cardiovascular de Colombia Identifier: NCT00317629    
Other Study ID Numbers: fcv137
First Posted: April 25, 2006    Key Record Dates
Last Update Posted: November 24, 2010
Last Verified: November 2010
Keywords provided by Fundación Cardiovascular de Colombia:
nitric oxide
controlled trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Leishmaniasis, Cutaneous
Euglenozoa Infections
Protozoan Infections
Parasitic Diseases
Skin Diseases, Parasitic
Vector Borne Diseases
Skin Diseases, Infectious
Skin Diseases
Meglumine Antimoniate
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Protective Agents
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents